Clinical Trial · NCT03164486

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Overview

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Sponsor

University of California, Davis

Phase

Early Phase 1

Contacts

Julie Sutcliffe (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03164486

Drug / Compound

αvβ6-BP

Isotope(s):

Target(s):

αvβ6

Ligand Class: Peptides

Eligibility

Inclusion

Will sign the Institutional Review Board (IRB)-approved consent form
* Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
Able to remain motionless for up to 30-60 minutes per scan

Exclusion

Life expectancy \< 3 months (mo)
Patients who cannot undergo PET/compute tomography (CT) scanning
* Creatinine \> 2 x upper limit of normal
Women who are pregnant or breast-feeding
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 x upper limit of normal